Helsinn Corporate
Search
About Us
Our Mission, Vision and Values
Board and Management
History and Milestones
Research Grant
Locations
Careers
Our Business
Business Model
Research and Development
Drug Manufacturing
Partnerships
US Operations
China Operations
Investment Fund
Our Products
Cancer Therapeutics
Cancer Supportive Care
Pain & inflammation
Gastroenterology
Social Responsibility
For Cancer Patients
Our People
Our Communities
Our Environment
Acting Responsibly
Integrity Portal
Grant Requests
News and Events
Sitemap
Home
About Us
Careers
Grow in Helsinn
Internships at Helsinn – Ticino Talent Project
Scholarships
Internships at Helsinn – Progetto Talenti Ticino
Board and Management
History and Milestones
Locations
Our Mission, Vision and Values
Research Grant
Our Business
Business Model
Research and Development
Pipeline
Late Phase Development
Drug Manufacturing
State-of-the-Art Drug Manufacturing
Helsinn Advanced Synthesis
Helsinn Birex Pharmaceuticals Ltd., Dublin (HBP)
Partnerships
Current Partnerships
Supporting Our Partners
Partner With Us
In-Licensing
Out-Licensing
US Operations
Helsinn Investment Fund
China Operations
中国业务
Our Products
Cancer Supportive Care
Pain & inflammation
Gastroenterology
Cancer Therapeutics
Corporate Social Responsibility and Sustainability
For Cancer Patients
Advocacy Groups
Our People
Working at Helsinn
Health and Safety at Work
Our Communities
Our Environment
Acting Responsibly
Compliance Program
Quality Assurance System
Grant Requests
Integrity Portal
Commitment
Standards
Reporting Channels
Codes of Conduct
Resolving Issues
Training and Communication
FAQ
News and Events
Helsinn announces publication of anamorelin ROMANA 1 and ROMANA 2 Phase III studies in The Lancet Oncology
Helsinn to present at ASCO pooled follow up efficacy data analysis from two Phase III studies for anamorelin in cachectic patients with NSCLC
Agreement with Grünenthal for AKYNZEO® in Chile
Helsinn attendance at ASCO 2016
Helsinn attendance at ESMO 2016
Blog Category
Helsinn to Present at UBS Healthcare Conference in New York
Helsinn CEO Riccardo Braglia to present at the Jefferies 2014 Healthcare Conference
New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology
Data presented at the International Society of Paediatric Oncology (SIOP) Congress show Palonosetron is a valuable option for treating pediatric patie
10 young students from the sopraceneri area receive Helsinn Advanced Synthesis SA 2013/2014 Educational Scholarships
Helsinn and Chugai Pharma Marketing enter into agreement for rights of Anamorelin, currently in development for treatment of anorexia-cachexia syndrom
Helsinn Birex Pharmaceuticals wins two prestigious awards for its outstanding health and safety performance
Helsinn Group's representative office in China: official inauguration
Helsinn Group and EISAI announce FDA acceptance of New Drug application for investigational compound netupitant 300 mg + palonestron 0.50 mg (NEPA)
Helsinn and Italfarmaco reinforce their alliance through the grant of rights to phase-III ghrelin receptor agoni st Anamorelin in Italy
Presentato il rapporto di sostenibilità 2012 di Helsinn Advanced Synthesis SA, presente a Biasca da 30 anni
Data presented at the International Society of Paediatric Oncology (SIOP) Congress show Palonosetron is a valuable option for treating pediatric patients receiving moderately to highly emetogenic chemotherapy
FDA Approves AKYNZEO® (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
Helsinn’s showcase as part of "Piazza Ticino" at CPhI 2014, October 7-9, 2014, in Paris
Pivotal Phase III Trial Data for anamorelinin ROMANA 1 and 2 Studies in Non-Small Cell Lung Cancer Patients with Anorexia-Cachexia Shows Significant Increase in Lean Body Mass, Body Weight and Improved Symptoms
Helsinn to provide independent educational grant support for a satellite symposium on Delivering Chemotherapy with Confidence
Helsinn Group Receives Positive CHMP Opinion for Akynzeo® (netupitant/palonosetron) for the Prevention of Chemotherapy Induced Nausea and Vomiting
HELSINN GROUP GRANTS STENDHAL INTERNATIONAL EXCLUSIVE RIGHTS TO THE DISTRIBUTION AND MARKETING OF NETUPITANT-PALONOSETRON (NEPA) IN MULTIPLE COUNTRIES
Helsinn to present at the 33rd Annual J.P. Morgan Healthcare Conference (January 12-15, 2015)
30 candeline per la Helsinn Advanced Synthesis di Biasca, all'Insegna della Solidarietà - Helsinn Advanced Synthesis Celebrates 30 Year Anniversary and Supports the Social Activities of Volunteer Associations
Helsinn Awards Scholarships for Advanced Synthesis Education to 11 Students for the Academic Year 2014/2015 - Borse di Studio Helsinn Advanced Synthesis 2014/2015 per 11 Giovani Studenti del Canton Ticino per 55.000.- CHF
Helsinn Publishes Sustainability Report for its Drug Product Manufacturing and Supply Operation in Ireland
Helsinn Advanced Synthesis Wins 2015 CMO Leadership Award
HELSINN GROUP SIGNS EXCLUSIVE AGREEMENT WITH MUNDIPHARMA FOR DISTRIBUTION AND LICENCE OF ANAMORELIN IN CHINA, HONG KONG AND MACAO
EXCLUSIVE AGREEMENTS WITH MUNDIPHARMA FOR DISTRIBUTION AND LICENCE OF ANAMORELIN IN BRAZIL & ACROSS KEY MARKETS IN THE MIDDLE EAST & NORTH AFRICA
HELSINN GROUP SIGNS EXCLUSIVE AGREEMENT WITH MUNDIPHARMA FOR DISTRIBUTION AND LICENSING OF NETUPITANT/PALONOSETRON (NEPA) IN BRAZIL
Helsinn and Zealand announce the advance of elsiglutide into Phase IIB development for the prevention of chemotherapy-induced diarrhea
Helsinn Group and Eisai Inc. Announce Inclusion of AKYNZEO® (netupitant/palonosetron) in 2015 NCCN® Antiemesis Guidelines
TGA Approves AKYNZEO® (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
Helsinn Group to present data at 2015 ASCO
The EU Commission approves ALOXI® (palonosetron HCl) Injection to prevent nausea and vomiting due to chemotherapy in children as young as one month
Helsinn introduces Helsinn Integrative Care at the American Society of Clinical Oncology Annual Meeting
The EU Commission Approves Helsinn’s Akynzeo®(netupitant/palonosetron) for Prevention of Chemotherapy-Induced Nausea and Vomiting in European Union
Helsinn Group hosts a Satellite Symposium on best practice in treating nausea in cancer patients, at MASCC
HELSINN GROUP SIGNS EXCLUSIVE AGREEMENT WITH MUNDIPHARMA FOR THE DISTRIBUTION AND LICENCE OF ANAMORELIN IN SWITZERLAND AND LIECHTENSTEIN
HELSINN GROUP SIGNS EXCLUSIVE AGREEMENT WITH BIAL FOR DISTRIBUTION AND LICENCE OF ANAMORELIN IN SPAIN, PORTUGAL, ANGOLA AND MOZAMBIQUE
Additional data for anamorelin in ROMANA 1 and ROMANA 2 studies
Launch of Netupitant-Palonosetron Fixed Combination (Akynzeo®) in the UK by Chugai Pharma UK Ltd
HELSINN GROUP AWARDED GLOBAL CEO CANCER GOLD STANDARD ACCREDITATION
Helsinn Reaches Settlement Agreement Regarding Patent Dispute on ALOXI®
Helsinn’s AKYNZEO® (netupitant/palonosetron) nominated within the category “Best Pharmaceutical Agent of the Year” at The Galien Foundation Prix Award
Helsinn Group and Eisai Inc. Announce Inclusion of AKYNZEO® (netupitant/palonosetron) in American Society of Clinical Oncology (ASCO) Antiemetics Guid
SUCCESSFUL RULING IN PATENT INFRINGEMENT LITIGATION FOR ANTIEMETIC AGENT ALOXI® IN THE UNITED STATES
11 HELSINN ADVANCED SYNTHESIS 2014/2015 EDUCATIONAL SCHOLARSHIPS AWARDED TO YOUNG STUDENTS IN CANTON TICINO FOR 55.000 CHF
HELSINN ANNOUNCES EUROPEAN MEDICINES AGENCY ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATION FOR ANAMORELIN HCL
Swissmedic approves Akynzeo® (netupitant/palonosetron) for use in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Switzerland
HELSINN CELEBRATES ITS 40th ANNIVERSARY - ~ 40 years helping patients achieve a better quality of life ~
HELSINN GROUP SIGNS EXCLUSIVE AGREEMENT WITH MUNDIPHARMA FOR THE DISTRIBUTION AND LICENCE OF ANAMORELIN IN NORTHERN EUROPE COUNTRIES
Helsinn and Eisai Announce Revised U.S. Collaboration for CINV Franchise
Helsinn announces publication of anamorelin ROMANA 1 and ROMANA 2 Phase III studies in The Lancet Oncology
Helsinn presents Quality of Life, its first group sustainability report
Helsinn Advanced Synthesis SA Wins 2016 CMO Leadership Awards
Helsinn Supports the Development of NCCN Guidelines For Patients® on Nausea and Vomiting, with a Sponsorship Grant
HELSINN GROUP SIGNS EXCLUSIVE AGREEMENT WITH PURDUE PHARMA CANADA FOR THE DISTRIBUTION AND LICENSING RIGHTS OF AKYNZEO® (NETUPITANT/PALONOSETRON combo
Helsinn Healthcare,The University of Texas MD Anderson Cancer Center enter strategic alliance to improve life of patients conducting clinical studies
Helsinn supports Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care with research funding support
Helsinn announces top-line results of Phase IIb trial with elsiglutide for prevention of chemotherapy-induced diarrhea in colorectal cancer patients
Helsinn to Present at UBS Healthcare Conference in New York
Helsinn to present at ASCO pooled follow up efficacy data analysis from two Phase III studies for anamorelin in cachectic patients with NSCLC
HELSINN GROUP SIGNS EXCLUSIVE AGREEMENT WITH GRÜNENTHAL GROUP FOR THE REGISTRATION, MARKETING, PROMOTION AND SALES OF AKYNZEO®
Helsinn Group hosts a Satellite Symposium on shared decision making in supportive care, at MASCC on June 24
Helsinn Group signs agreement with Vifor Pharma for the promotion and distribution of ALOXI®
Helsinn Group and MEI Pharma Enter Strategic Agreement for the Development of Pracinostat for the Treatment Myeloid Leukemia and Other Diseases
Helsinn and PatientsLikeMe Announce Results of NSCLC Patient Survey on Weight Loss
HELSINN ATTENDANCE AT CPHI 2016
HELSINN GROUP INTRODUCES HELSINN INVESTMENT FUND
Swissmedic approves ALOXI® for use in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Children in Switzerland
Helsinn Group and MEI Pharma Announce Long-Term Survival and Response Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia Accepted for Oral Presentation at Upcoming American Society of Hematology Annual Meeting - Data to be present
HELSINN ADVANCED SYNTHESIS 2016/2017 EDUCATION SCHOLARSHIPS FOR 11 STUDENTS IN CANTON TICINO FOR A TOTAL OF 55.000.-
Helsinn Integrative Care Announces 510(K) FDA Clearance for Medical Device Xonrid® Gel
Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
Helsinn Attendance at J.P. Morgan Annual Healthcare Conference
Helsinn will attend at ASCO 2017
ESMO 2017 in Madrid
Helsinn Group Launches “Helsinn Cares” Patient Support Services
Mundipharma and Helsinn Group Expand Exclusive Licensing and Distribution Agreements for Leading Anti-emetic Products in Middle East, Africa, Latin America and Indonesia
DCAT 2017 - New York City
CPhI Japan-2017
Helsinn Provides Grant for ESMO’s Preceptorship Course on Supportive and Palliative Care
HELSINN SUPPORTING FIRST ESMO PRECEPTORSHIP ON SUPPORTIVE AND PALLIATIVE CARE
Palliative and Supportive Care in Oncology Symposium
Helsinn Advanced Synthesis announces investment - Helsinn Advanced Synthesis annuncia investimenti
Helsinn Collaborates with Lyfebulb to Support Patient-Driven Innovations for People with Cancer
Helsinn Advanced Synthesis wins across all categories 2017 CMO Leadership Awards
Helsinn Healthcare vs. Teva Pharmaceuticals on Aloxi® patent for the US market
HELSINN INVESTMENT FUND INVESTS IN AADI BIOSCIENCE
Helsinn Investment Fund leads the financial round in GreenBone
Helsinn appoints Eric Cornut to Board of Directors
Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
Helsinn to Present at UBS Global Healthcare Conference in New York
Helsinn Birex Pharmaceuticals wins National Workplace Wellbeing Day Award
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome
Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
First Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Sarah A. Buckley, MD, University of Washington
Helsinn Group signs Exclusive Agreement with Purdue Pharma (Canada) for the Distribution and Licensing Rights of Aloxi® (palonosetron hydrochloride) in Canada
Zealand to regain control of elsiglutide
Helsinn Group Announces Upcoming Presentation of Phase III data in NEPA (netupitant/palonestron) at MASCC/ISOO Congress in Washington DC
APSHO
Chemotherapy Foundation Symposium - 2017
Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
CPhI Worldwide 2017
AMAL Therapeutics raises €8 million (CHF 8.8 million) in first closing of Series B financing round
Helsinn Therapeutics (U.S.) Inc., Signs Co-Promotion Agreement for Cancer Therapeutic Zykadia® in the US
Helsinn Group Announces Upcoming Presentation of Phase III data of NEPA (fosnetupitant/ palonosetron) IV at ESMO 2017
Helsinn Group supports prIME’s Satellite Symposium at ESMO 2017
Helsinn Advanced Synthesis 2017/2018 education scholarships for 10 students in canton Ticino for a total of 50.000.- CHF
Helsinn announces its support for the International Fellowship Program (IFP), a joint project founded by the Society for Translational Oncology (STO) and Chinese Society of Clinical Oncology (CSCO)
Helsinn Pharmaceuticals (Beijing) Co. Ltd. Opens Office in Shanghai, China
Helsinn Announces Attendance at the CPhI 2017 Conference in Frankfurt
A call for action to patient entrepreneurs in the area of cancer to compete at the Lyfebulb-Helsinn Summit for the first ever Lyfebulb- Helsinn Innovation Award
40th SAN ANTONIO BREAST CANCER SYMPOSIUM
59th ASH ANNUAL MEETING AND EXPOSITION
Helsinn Group supports Satellite Symposium at 10th International Conference on Cachexia, Sarcopenia and Muscle Wasting
Helsinn to honor Anna Braglia Endowed Young Investigator Award recipient at Helsinn reception during JP Morgan Healthcare Conference 2018
A call for action to patient entrepreneurs in the area of cancer to compete at the Lyfebulb-Helsinn Summit for the first ever Lyfebulb - Helsinn Innovation Award
Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML)
US Court of Appeals for Federal Circuit Rejects Petition by Helsinn for Rehearing En Banc of Federal Circuit Panel Ruling That Certain Patents Covering Aloxi® in the US Market Are Invalid
Borse di studio Helsinn Advanced Synthesis 2017/2018 per 10 studenti del canton Ticino per un valore complessivo di 50'000.- CHF
Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement
Helsinn Group announces the appointment of Paul Rittman as Chief Executive Officer, Helsinn Therapeutics (HTU)
Helsinn Files Petition for Writ of Certiorari for Supreme Court Review Regarding Patent Covering Aloxi® in the US Market
Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology
On Target Laboratories Raises Additional Capital from H.I.G. BioHealth Partners, Elevate Ventures and Helsinn
Helsinn Group Announces First Patient Enrolled in Phase 3b Study of NEPA IV vs NEPA Oral for the prevention of chemotherapy induced nausea and vomiting (CINV) in Women with Breast Cancer
Helsinn Group announces agreement to acquire worldwide rights to Valchlor®/Ledaga® - an approved and marketed alkylating agent for the topical treatment of mycosis fungoides‐type cutaneous T‐cell lymphoma, a rare type of skin cancer
Helsinn Advanced Synthesis wins across all categories at the 2018 CMO Leadership Awards
Winners of the inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced
Helsinn Group and Glenmark Pharmaceuticals enter into an exclusive licensing agreement for launch of AKYNZEO® in India and Nepal
Helsinn Provides Grant for ESMO’s Preceptorship Programme for Supportive and Palliative Care
Transforming Breast Cancer Together: A Call for Change
VITAFOOD Europe 2018
ESTRO
Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/palonosetron) in the United States
Helsinn Group to Present a Poster at Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2018
NovellusDx announces it has completed an equity financing of $6 million
Helsinn Group announces the launch of the IV formulation of AKYNZEO® (fosnetupitant/palonosetron) in the United States
Helsinn Group and Mundipharma announce the launch of AKYNZEO® hard capsule for oral use in Brazil
Helsinn announces EUR6 million investment in Helsinn Birex Pharmaceuticals to safeguard the quality and authenticity of its products
ASCO
MASCC
Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the design of the Phase III PRIMULA study of Pracinostat in combination with azacitidine for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit for standard ind
MEI Pharma and Helsinn Group Announce Successful Interim Analysis of Pracinostat/Azacitidine Phase 2 Combination Study in Higher Risk Myelodysplastic Syndrome (MDS) Patients
Second Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Rajiv Agarwal, MD, Memorial Sloan Kettering Cancer Center
Helsinn Group and Angelini support Satellite Symposium at MASCC/ISOO 2018 Annual Meeting
The US Supreme Court Grants Review for Certiorari of a Federal Circuit Panel Ruling that US Patent Protection for Aloxi® in the US Market was Invalid
Helsinn Therapeutics (U.S.) Inc. becomes the exclusive distributor of ALOXI® (palonosetron HCI) in the U.S.
Glenmark Pharmaceuticals expands its oncology franchise in India with the launch of Helsinn’s AKYNZEO®, a combination drug for the prevention of chemotherapy-induced nausea and vomiting (CINV)
Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea
Mundipharma brings its cancer supportive care expertise to Vietnam after signing agreement with Helsinn Group for ALOXI® (palonosetron HCl)
Helsinn Group supports Satellite Symposium at EORTC CLTF 2018 Annual Meeting
ONO Submits an Application for Manufacturing and Marketing Approval of Anamorelin (ONO-7643), a ghrelin receptor antagonist, for the treatment of cancer cachexia in Japan
Helsinn Group strengthens the Board with the appointment of Francesco Granata - Il Gruppo Helsinn rafforza il Consiglio di Amministrazione con la nomina di Francesco Granata
EORTC
ESMO
EADO
Helsinn Group supports Satellite Symposium at 14th EADO Congress 2018
Helsinn and Lyfebulb Announce Partnership for Second Annual Patient-Driven Innovation Summit in Cancer
Helsinn and Mundipharma China Pharmaceutical announce tha approval of ALOXI®IV by the National Medical Products Administration in China
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting
Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US
Recordati and Helsinn Sign an Agreement for the Exclusive Commercialization Rights to Ledaga®
Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat
JP Morgan
CPhI Japan
DCAT
Helsinn Provides Educational Grant for ESMO’s Preceptorship for Supportive and Palliative Care
Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in the Frontline Treatment of Older AML Patients Unfit for Intensive Chemotherapy, in Blood Advance
Helsinn Investment Fund Invests €1 Million in Gain Therapeutics
Ten finalists have been chosen for the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology
Helsinn initiates two new global Phase III studies with anamorelin
Vitafoods Europe
Winners of the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced
Helsinn Supports Local Art Exhibition, ‘Lugano: Reflections of Light’ by Helidon Xhixha, curated by Eike D. Schmidt - Helsinn sostiene la mostra d’arte a cielo aperto Lugano: Riflessi di Luce, di Helidon Xhixha, curata da Eike D. Schmidt
Helsinn nominated as a Swiss Biotech Success Story 2019/2020 by the Swiss Biotech Association
Helsinn and Mundipharma China Pharmaceutical together announce the launch of ALOXI® IV in China and a Co-Detailing collaboration in Shanghai
ASCO 2019
MASCC 2019
Helsinn Group Announces Upcoming Presentation of Phase 3b data of NEPA (fosnetupitant / palonosetron) IV at ASCO 2019
Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Allison Barz Leahy, MD, University of Pennsylvania
Helsinn Group supports two events with the International Society for Cutaneous Lymphomas (ISCL) at the 24th World Congress of Dermatology
Helsinn Healthcare SA Sues Nang Kuang Pharmaceutical Co. Ltd. for Patent Infringement in Taiwan
Helsinn to co-support a satellite symposium on current and emerging treatments of Acute Myeloid Leukemia (AML) at 24th European Hematology Association (EHA) Congress
Helsinn appoints Giorgio Calderari, Group General Manager and Chief Operating Officer, to the Board of Directors
Helsinn Investment Fund Announces First Exit
Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada
Helsinn and Lyfebulb Announce Third Annual Patient-Driven Innovation Summit & Award in Oncology to be held during the 14th Monaco Biennale of Oncology 2020
Helsinn signs exclusive distribution and license agreements with Blanver and Varifarma for Pracinostat in South America
Helsinn and Mundipharma China Pharmaceutical jointly announce NMPA’s approval of the oral formulation of Akynzeo® in China
ESDR
EORTC
EADV
Helsinn and Lyfebulb Announce Call for Applications for Third Annual Patient-Driven Innovation Summit & Award in Oncology
Helsinn announces abstract accepted for oral presentation at the EORTC Cutaneous Lymphoma Meeting 2019
Helsinn appoints Eric Cornut and Lonnie Moulder to the Board of Directors
Helsinn demonstrates commitment to MF CTCL with multiple scientific sessions at the EORTC Cutaneous Lymphoma Meeting 2019
Helsinn to co-host alongside Recordati Rare Diseases satellite symposium on MF-CTCL diagnosis optimization at European Academy of Dermatology and Venereology Congress 2019
Helsinn attends 4th Annual Sino-Swiss Business Awards
Helsinn supported ‘70 Years of Cancer Care in China’ celebratory event in Shanghai
Helsinn Advanced Synthesis, Biasca: Reduces CO2 emissions by 80% and unveils the new anticancer plant
Helsinn Advanced Synthesis, Biasca: Riduce dell’80% l’emissione CO2 e inaugura il nuovo impianto oncologico
Helsinn to present a scientific poster on acute care use following CINV prophylaxis with agents in breast cancer patients at the San Antonio Breast Cancer Symposium (SABCS) 2019
Lyfebulb and Helsinn Announce 11 Finalists for the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award
Helsinn Group Grants Exclusive Licensing Rights to Berlin-Chemie AG, a company of the Menarini Group, for ONICIT®/ALOXI® and AKYNZEO® in Russia and CIS region
Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award
4th World Congress of Cutaneous Lymphomas (WCCL)
New Insights on Mechlorethamine/Chlormethine gel presented at 4th World Congress of Cutaneous Lymphomas
Helsinn announces European approval of the IV formulation of AKYNZEO® (fosnetupitant / palonosetron)
Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VALCHLOR® (mechlorethamine) gel to ensure eligible patients have access to treatment during the COVID-19 crisis
Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine in Patients with High/Very-high Risk Myelodysplastic Syndromes
Helsinn Group announces FDA approval of a new liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) injection in the United States
Helsinn announces FDA acceptance of IND application for TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
Helsinn announces launch of oral formulation of Akynzeo® in China
Helsinn Group supports Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund
Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis
3B Future Health Fund announces new investment in iOnctura
Downloads
Contact Us
Terms of use
Sitemap
Privacy and Cookies Policy
Borse di studio HAS 2017
Helsinn Community Guidelines
COVID-19
Our website uses cookies
By using Helsinn Group website you agree to our
use of cookies
to enhance your experience.
×